Literature DB >> 20425077

Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy.

Mario Scartozzi1, Mirco Pistelli, Alessandro Bittoni, Riccardo Giampieri, Eva Galizia, Rossana Berardi, Luca Faloppi, Michela Del Prete, Stefano Cascinu.   

Abstract

Although recent advances have been made, surgery still remains the mainstay of any curative treatment for gastric cancer patients, with radical gastrectomy representing the procedure of choice. However, patients with locally advanced disease show high rates of locoregional or distant recurrence even after potentially curative resections. According to global results presented in the setting of locally advanced resectable gastric carcinoma, perioperative chemotherapy may be considered a valuable option. On the other hand, clinical trials for advanced gastric cancer seem to suggest that a limit in efficacy has been reached for standard chemotherapy. Interesting data are expected from the development of targeted agents that, similarly to other cancer sites, showed appealing results in gastric cancer as well. Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425077     DOI: 10.1007/s11912-010-0101-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  29 in total

1.  Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).

Authors:  E Mari; I Floriani; A Tinazzi; A Buda; M Belfiglio; M Valentini; S Cascinu; S Barni; R Labianca; V Torri
Journal:  Ann Oncol       Date:  2000-07       Impact factor: 32.976

2.  Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group.

Authors:  E Bajetta; R Buzzoni; L Mariani; E Beretta; F Bozzetti; G Bordogna; E Aitini; S Fava; G Schieppati; G Pinotti; M Visini; G Ianniello; Bartolomeo M Di
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

3.  A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

Authors:  Chul Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Tae Won Kim; Ho Young Lim; Hye Jin Kang; Young Suk Park; Baek-Yeol Ryoo; Yoon-Koo Kang
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

4.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Authors:  M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

5.  Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.

Authors:  Chul Kim; Jae-Lyun Lee; Yoon Hee Choi; Byung Woog Kang; Min-Hee Ryu; Heung Moon Chang; Tae Won Kim; Yoon-Koo Kang
Journal:  Invest New Drugs       Date:  2010-09-14       Impact factor: 3.850

6.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

Review 7.  Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.

Authors:  Jaume Capdevila; Elena Elez; Teresa Macarulla; Francisco Javier Ramos; Manuel Ruiz-Echarri; Josep Tabernero
Journal:  Cancer Treat Rev       Date:  2009-03-06       Impact factor: 12.111

8.  Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.

Authors:  Francesco Di Costanzo; Silvia Gasperoni; Luigi Manzione; Giancarlo Bisagni; Roberto Labianca; Stefano Bravi; Enrico Cortesi; Paolo Carlini; Raffaella Bracci; Silverio Tomao; Luca Messerini; Annarosa Arcangeli; Valter Torri; Domenico Bilancia; Irene Floriani; Maurizio Tonato; Angelo Dinota; Gennaro Strafiuso; Enrichetta Corgna; Stella Porrozzi; Corrado Boni; Ermanno Rondini; Alessandro Giunta; Barbara Monzio Compagnoni; Franco Biagioni; Maurizio Cesari; Giuseppe Fornarini; Fabrizio Nelli; Manlio Carboni; Francesco Cognetti; Maria Ruggeri Enzo; Andrea Piga; Adriana Romiti; Alessandra Olivetti; Luigi Masoni; Marinella De Stefanis; Angelo Dalla Mola; Salvatore Camera; Francesco Recchia; Sandro De Filippis; Loreto Scipioni; Sandra Zironi; Gabriele Luppi; Maurizio Italia; Stefano Banducci; Andrea Pisani Leretti; Bruno Massidda; Maria Teresa Ionta; Angelo Nicolosi; Rodolfo Canaletti; Bruno Biscottini; Fausto Grigniani; Federica Di Costanzo; Rossella Rovei; Enrico Croce; Rosalia Carroccio; Germana Gilli; Carla Cavalli; Angelo Olgiati; Umberto Pandolfi; Riccardo Rossetti; Giovanni Natalini; Paolo Foa; Sabina Oldani; Lorenzo Bruno; Stefano Cascinu; Giuseppina Catalano; Vincenzo Catalano; Ferdinando Lungarotti; Antonio Farris; Maria Giuseppina Sarobba; Mario Trignano; Antonio Muscogiuri; Fontana Francavilla; Franco Figoli; Maurizio Leoni; Giorgio Papiani; Gianfranco Orselli; Mauro Antimi; Vincenzo Bellini; Alessandro Cabassi; Antonio Contu; Antonio Pazzola; Mario Frignano; Elena Lastraioli; Matilde Saggese; Diletta Bianchini; Lorenzo Antonuzzo; Micol Mela; Roberta Camisa
Journal:  J Natl Cancer Inst       Date:  2008-03-11       Impact factor: 13.506

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.

Authors:  Stefano Cascinu; Roberto Labianca; Carlo Barone; Armando Santoro; Carlo Carnaghi; Alessandra Cassano; Giordano D Beretta; Vincenzo Catalano; Oscar Bertetto; Sandro Barni; Luciano Frontini; Enrico Aitini; Silvia Rota; Valter Torri; Irene Floriani; Carmelo Pozzo; Lorenza Rimassa; Stefania Mosconi; Paolo Giordani; Antonio Ardizzoia; Paolo Foa; Carla Rabbi; Silvana Chiara; Giampietro Gasparini; Mario Nardi; Mauro Mansutti; Ermenegildo Arnoldi; Elena Piazza; Enrico Cortesi; Francesca Pucci; Rosa Rita Silva; Alberto Sobrero; Alberto Ravaioli
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

View more
  8 in total

1.  Introduction: personalized medicine in gastrointestinal cancer.

Authors:  Taylor S Riall
Journal:  J Gastrointest Surg       Date:  2012-06-30       Impact factor: 3.452

2.  Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.

Authors:  Hiroshi Yoshida; Noriko Yamamoto; Hirokazu Taniguchi; Ichiro Oda; Hitoshi Katai; Ryoji Kushima; Hitoshi Tsuda
Journal:  Virchows Arch       Date:  2014-06-03       Impact factor: 4.064

Review 3.  Integrating traditional medicine into modern inflammatory diseases care: multitargeting by Rhus verniciflua Stokes.

Authors:  Ji Hye Kim; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Mediators Inflamm       Date:  2014-06-12       Impact factor: 4.711

4.  Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis.

Authors:  M Kamran; Z-J Long; D Xu; S-S Lv; B Liu; C-L Wang; J Xu; E W-F Lam; Q Liu
Journal:  Oncogenesis       Date:  2017-02-20       Impact factor: 7.485

5.  Optimizing miRNA-module diagnostic biomarkers of gastric carcinoma via integrated network analysis.

Authors:  Fengbin Zhang; Wenjuan Xu; Jun Liu; Xiaoyan Liu; Bingjie Huo; Bing Li; Zhong Wang
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

Review 6.  HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.

Authors:  Valentina Fanotto; Elena Ongaro; Karim Rihawi; Antonio Avallone; Nicola Silvestris; Lorenzo Fornaro; Enrico Vasile; Lorenzo Antonuzzo; Francesco Leone; Gerardo Rosati; Francesco Giuliani; Roberto Bordonaro; Mario Scartozzi; Giovanna De Maglio; Francesca V Negri; Gianpiero Fasola; Giuseppe Aprile
Journal:  Oncotarget       Date:  2016-10-18

7.  FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer.

Authors:  Hui-Wen Chiu; Jeng-Shou Chang; Hui-Yu Lin; Hsun-Hua Lee; Chia-Hao Kuei; Che-Hsuan Lin; Huei-Mei Huang; Yuan-Feng Lin
Journal:  J Clin Med       Date:  2018-10-06       Impact factor: 4.241

8.  Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery.

Authors:  Yonghe Chen; Dan Liu; Jian Xiao; Jun Xiang; Aihong Liu; Shi Chen; Junjie Liu; Xiansheng Hu; Junsheng Peng
Journal:  Gastroenterol Res Pract       Date:  2021-07-28       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.